No Data
shanghai kaibao pharmaceutical (300039.SZ) and its subsidiaries have a total of 91 pharmaceuticals included in the National Medical Insurance Catalogue.
Shanghai Kaibao (300039.SZ) announced that the company and its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co. ...
Shanghai Kaibao PharmaceuticalLtd (SZSE:300039) Sheds 5.6% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Shanghai Kaibao: Report for the third quarter of 2024
Shanghai Kaibao Pharmaceutical (300039.SZ): The net income for the first three quarters was 0.217 billion yuan, a year-on-year increase of 10.68%.
Gelonghui on October 24th: shanghai kaibao pharmaceutical (300039.SZ) announced its third quarter report for 2024, with the company achieving revenue of 1.121 billion yuan in the first three quarters, a year-on-year decrease of 2.87%; net income attributable to shareholders of the listed company was 0.217 billion yuan, a year-on-year increase of 10.68%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.212 billion yuan, a year-on-year increase of 11.93%; basic earnings per share was 0.2075 yuan.
Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Market Cap Rose CN¥397m Last Week; Retail Investors Who Hold 56% Profited and so Did Insiders
shanghai kaibao pharmaceutical (300039.SZ): The company's products Phlegm-heat-clearing injection and Phlegm-heat-clearing capsules are currently not being sold in the Hong Kong and Taiwan regions.
GeLonghui September 23rd | shanghai kaibao pharmaceutical (300039.SZ) stated on the investor interaction platform that the company's products Tan Reqing Injection and Tan Reqing Capsules are currently not sold in Hong Kong and Taiwan.
The Market Doesn't Like What It Sees From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Earnings Yet